A simulation study of approaches for handling disease progression in dose-finding clinical trials.

Abstract:

:In traditional dose-finding studies, dose-limiting toxicity (DLT) is determined within a fixed time observation window where DLT is often defined as a binary outcome. In the setting of oncology dose-finding trials, often patients in advanced stage of diseases are enrolled. Therefore, disease progression may occur within the DLT observation window leading to treatment discontinuation and rendering the patient unevaluable for DLT assessment. As a result, additional patients have to be enrolled, increasing the sample size. We propose and compare several practical approaches for handling disease progression which occurs within the DLT observation window, while in the framework of the time-to-event continual reassessment method (TITE-CRM) which allows using partial observations. The approaches differ on the way they define an evaluable patient and in the way incomplete observations are included. The practical approaches, which we call strategies A, B and C, are illustrated and contrasted in the context of a single simulated trial, and compared via simulations under various scenarios of dose-progression relationship, in the setting of advanced soft-tissue sarcoma.

journal_name

J Biopharm Stat

authors

Biard L,Cheng B,Manji GA,Lee SM

doi

10.1080/10543406.2020.1814796

subject

Has Abstract

pub_date

2020-09-15 00:00:00

pages

1-12

eissn

1054-3406

issn

1520-5711

pub_type

杂志文章
  • Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.

    abstract::When performing a pivotal clinical trial, it may be of interest to assess the probability of success (PoS) of that trial. Initially evaluated when the trial is designed, PoS can be updated as the trial progresses and new information about the drug effect becomes available. Such information can be external to the trial...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.972508

    authors: Rufibach K,Jordan P,Abt M

    更新日期:2016-01-01 00:00:00

  • Multiple testing of noninferiority hypotheses in active controlled trials.

    abstract::For noninferiority testing with the maximum allowable noninferiority margin being prespecified, one can perform valid statistical testing at the same alpha level for multiple noninferiority hypotheses with margins being smaller than this maximum margin. This is easily comprehensible because only one confidence level i...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120037183

    authors: Hung HM,Wang SJ

    更新日期:2004-05-01 00:00:00

  • Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.

    abstract::A new three-arm parallel design was recently proposed to investigate the biosimilarity between a biological product and a reference product by using the relative distance. The purpose of this article is to extend their results to binary endpoints for three popular metrics: the risk difference, the log relative risk, a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.979195

    authors: Shin W,Kang SH

    更新日期:2016-01-01 00:00:00

  • Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.

    abstract::To confirm results obtained from local evaluation at investigational centers, many oncology studies utilize blinded independent central review (BICR) to make assessments of the primary endpoint, progression-free survival (PFS). The comparison of data often leads to large discordances between these observations, castin...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.813516

    authors: Mannino FV,Amit O,Lahiri S

    更新日期:2013-01-01 00:00:00

  • Estimating treatment effects in clinical crossover trials.

    abstract::Some current approaches to modeling crossover trials in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Particular attention is paid to the AB/BA design, and the inadequacies of the once popular two-stage procedure are discussed in detail. The use of bas...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409808835233

    authors: Grieve A,Senn S

    更新日期:1998-05-01 00:00:00

  • Interval estimation of the proportion ratio in repeated binary measurements under a stratified randomized clinical trial with noncompliance.

    abstract::The proportion ratio (PR) of a positive response between an experimental treatment and a standard treatment (or placebo) is often used to measure the relative treatment efficacy in a randomized clinical trial (RCT). For ethical reasons, it is almost inevitable to encounter some patients not complying with their assign...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.508139

    authors: Lui KJ,Chang KC

    更新日期:2012-01-01 00:00:00

  • The analysis, interpretation, and presentation of quality of life data.

    abstract::All too often in clinical trials the assessment of quality of life is seen as a bolt-on study. Consequently insufficient consideration is often given to its design, collection, analysis and presentation, and its impact on the trial results and on clinical practice is minimal. In many trials quality of life is a key en...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120028506

    authors: Stephens R

    更新日期:2004-02-01 00:00:00

  • Survival analysis and prognosis for dementia patients.

    abstract::How long a dementia patient is cared for in the home before admission to a nursing home depends on the state of the patient and the state of the caregiver. Using 5-year follow-up data, the times until entry to nursing home and until death are modeled using a Cox survival model in which patient and caregiver variables ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409408835076

    authors: McGilchrist CA,Brodaty H,Peters KE,Harris L

    更新日期:1994-03-01 00:00:00

  • Modeling the covariance structure in pharmacokinetic crossover trials.

    abstract::Pharmacokinetic studies of drug and metabolite concentrations in the blood are usually conducted as crossover trials, especially in phases I and II. A longitudinal series of measurements is collected on each subject within each period. However, much of the dependence among such observations, within and between periods...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101186

    authors: Lindsey JK,Wang J,Byrom WD,Jones B

    更新日期:1999-08-01 00:00:00

  • Power approximation for the van Elteren test based on location-scale family of distributions.

    abstract::The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600762939

    authors: Zhao YD,Qu Y,Rahardja D

    更新日期:2006-01-01 00:00:00

  • Conditional and unconditional confidence intervals following a group sequential test.

    abstract::After a group sequential test, the naive confidence interval (CI) is usually biased in the sense that it does not cover the true parameter at the correct nominal level. Furthermore, when the stopping time is taken into account, the actual conditional confidence coverage probability can be much less accurate. In this a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400500406595

    authors: Fan X,DeMets DL

    更新日期:2006-01-01 00:00:00

  • Parametric two-stage sequential quality assurance test of dose content uniformity.

    abstract::The United States Pharmacopeia (USP) content uniformity sampling acceptance plan consisting of a two-stage sampling plan with criteria on sample mean and number of out-of-range tablets is the standard for compendium. It is, however, often used mistakenly for lot quality assurance. In comparison to the Japan Phamacopei...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400601001527

    authors: Tsong Y,Shen M

    更新日期:2007-01-01 00:00:00

  • Equivalence tests for shelf life and average drug content in stability studies.

    abstract::Stability testing is a procedure frequently used in the pharmaceutical industry to estimate the shelf life of a drug. Hereby, a standard problem of interest is whether or not to pool a given number of batches to assign a single shelf life for the combined batches. In this paper, we propose two modified methods for the...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802287230

    authors: Djira GD,Hothorn LA,Tsong Y

    更新日期:2008-01-01 00:00:00

  • Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.

    abstract::There is often a need to determine parallelism or linearity between pairs of dose-response data sets for various biological applications. This article describes a technique based on a modification of the well-known extra-sum-of-squares principle of statistical regression. The standard extra-sum-of-squares method uses ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200056532

    authors: Gottschalk PG,Dunn JR

    更新日期:2005-01-01 00:00:00

  • Inference for clinical trials with some protocol amendments.

    abstract::The use of adaptive methods in clinical development has become very popular in recent years due to its flexibility in modifying trial procedures and/or statistical procedures of on-going clinical trials. Modifications to trial procedures are usually documented by protocol amendments. However, the actual patient popula...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200062286

    authors: Chow SC,Shao J

    更新日期:2005-01-01 00:00:00

  • Strategies for changing the test statistic during a clinical trial.

    abstract::This article discusses the design of a clinical trial where a new treatment will be compared to a control. For a specific type of endpoint, there are a wide variety of test statistics that can be used. Also, the investigator must decide how many patients to accrue in each arm as well as the duration of the study. Afte...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-120015743

    authors: Lawrence J

    更新日期:2002-05-01 00:00:00

  • Dunnett's many-to-one test and least square means.

    abstract::Dunnett's many-to-one test is used frequently today, especially in dose-finding studies. Using Dunnett's test, the Type I error level for the comparison between the raw mean of the control and the raw means of the study drug groups can be exactly calculated for the normal data. However, this computability depends on t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120017723

    authors: Shun Z,Silverberg A,Chang CK,Ouyang P

    更新日期:2003-02-01 00:00:00

  • Nonparametric step-down test procedures for finding minimum effective dose.

    abstract::Nonparametric versions of normal theory step-down multiple-test procedures for inferring minimum effective dose (see Tamhane et al. (1)) were developed and studied by Monte Carlo simulation. Two types of step-down testing procedures were examined. For both procedures, pairwise, linear, or Helmert contrasts of mean ran...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101173

    authors: Sidik K,Morris RW

    更新日期:1999-05-01 00:00:00

  • Estimation of the probability of passing the USP dissolution test.

    abstract::To ensure that a drug product will meet standards for identity, strength and stability as specified in the United States Pharmacopedia and National Formulary (USP/NF), it needs to pass a number of tests such as the content uniformity test and dissolution test at various stages of the manufacturing process. The sponsor...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701199536

    authors: Wang H

    更新日期:2007-01-01 00:00:00

  • A bootstrap-based test for establishing noninferiority in clinical trials.

    abstract::A randomized, active-control clinical trial setting with the objective of testing noninferiority for a continuous response variable is considered. Noninferiority margin is based on the concept of preserving a certain fraction of the active control effect. Noninferiority is established if the ratio of the lower (upper)...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600609478

    authors: Chen M,Kianifard F,Dhar SK

    更新日期:2006-05-01 00:00:00

  • Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

    abstract::In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedu...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971165

    authors: Wu J,Xiong X

    更新日期:2015-01-01 00:00:00

  • Factorial dose-response studies using frequency and magnitude of dose.

    abstract::In the early stages of traditional drug development, the frequency of dosing (e.g., QD, BID, etc.) is typically determined by the pharmacokinetic properties of a compound. After an appropriate dose frequency is chosen, the magnitude of dose is then evaluated via parallel-group dose-response trials. For some drugs, how...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835141

    authors: Hafner KB,Ruberg SJ

    更新日期:1996-07-01 00:00:00

  • Generalized estimating equations for multivariate response with the variates having different distributions.

    abstract::This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835129

    authors: May WL,Johnson WD

    更新日期:1996-05-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract::Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293075

    authors: Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期:2017-01-01 00:00:00

  • How to assess the relative range of two consecutive laboratory measurements to monitor patients.

    abstract::An integral part of routine health checkups involves laboratory measurements on various analytes in the blood. It is then common to compare the value of two consecutive measurements sampled at different times from the same patient. A "significant" change requires an action (additional sample and/or clinical action). T...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100107656

    authors: Cohen A,Doveh E,Umansky T

    更新日期:2001-01-01 00:00:00

  • Statistical innovations in the medical device world sparked by the FDA.

    abstract::The world of medical devices while highly diverse is extremely innovative, and this facilitates the adoption of innovative statistical techniques. Statisticians in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) have provided leadership in implementing statistical innova...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2015.1092037

    authors: Campbell G,Yue LQ

    更新日期:2016-01-01 00:00:00

  • Influence Analysis for the Area Under the Receiver Operating Characteristic Curve.

    abstract::Classification measures play essential roles in the assessment and construction of classifiers. Hence, determining how to prevent these measures from being affected by individual observations has become an important problem. In this paper, we propose several indexes based on the influence function and the concept of l...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1377728

    authors: Ke BS,Chiang AJ,Chang YI

    更新日期:2018-01-01 00:00:00

  • Non-normal random effects models for immunogenicity assay cut point determination.

    abstract::Administration of biological therapeutics can generate undesirable immune responses that may induce anti-drug antibodies (ADAs). Immunogenicity can negatively affect patients, ranging from mild reactive effect to hypersensitivity reactions or even serious autoimmune diseases. Assessment of immunogenicity is critical a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.972515

    authors: Zhang J,Yu B,Zhang L,Roskos L,Richman L,Yang H

    更新日期:2015-01-01 00:00:00

  • Simultaneous confidence interval methods for analytical similarity assessment.

    abstract::In analytical similarity assessment of a biosimilar product, key quality attributes of the test and reference products need to be shown statistically similar. When there were multiple references, similarity among the reference products is also required. We proposed a simultaneous confidence approach based on the fiduc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1657142

    authors: Zheng J,Yin D,Yuan M,Chow SC

    更新日期:2019-01-01 00:00:00

  • Identification of Risk Factors and Likelihood of Benefit from Adjuvant Chemotherapy for Early Stage Lung Cancer Patients.

    abstract::The purpose of the research is to develop a statistical decision support algorithm for patients who may benefit from Adjuvant Cisplatin/Vinorelbine (ACT) and improve their survival rates. Genome-wide microarray data are used to identify feasible sets of genes and probe sets that constitute the gene signature. The data...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1684310

    authors: Moon H,Chao T,Ahn H

    更新日期:2020-05-03 00:00:00